← feed

Is NCT03288740 results overdue?

Yes — results are overdue. Primary completion was 2018-07-10; the FDAAA-801 reporting deadline (2019-07-10) passed 2642 days ago and no results are posted on ClinicalTrials.gov.

A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects

NCT IDNCT03288740 ↗
SponsorNovo Nordisk A/S (INDUSTRY)
Public issuerNOVO NORDISK A S — NVO (CIK 0000353278) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-07-10 (ACTUAL)
Reporting deadline2019-07-10 (completion + 365d)
Days overdue2642
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-10-03 · SHA-256 eca549cc43711ab9… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03288740. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →